

Alice Marceau-Renaut

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3926372/publications.pdf>

Version: 2024-02-01

33
papers

1,041
citations

567281

15
h-index

477307

29
g-index

34
all docs

34
docs citations

34
times ranked

1698
citing authors

#	ARTICLE	IF	CITATIONS
1	Germline pathogenic variants in transcription factors predisposing to pediatric acute myeloid leukemia: results from the French ELAM02 trial. <i>Haematologica</i> , 2021, 106, 908-912.	3.5	8
2	Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. <i>Blood</i> , 2020, 135, 542-546.	1.4	62
3	The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 348-357.	7.2	44
4	Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia. <i>Blood</i> , 2019, 134, 2414-2416.	1.4	14
5	Germline <i>RUNX1</i> Intragenic Deletion: Implications for Accurate Diagnosis of FPD/AML. <i>HemaSphere</i> , 2019, 3, e203.	2.7	13
6	Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia. <i>Haematologica</i> , 2019, 104, 1150-1155.	3.5	14
7	Clinical relevance of <i>IDH1/2</i> mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group. <i>Haematologica</i> , 2018, 103, 822-829.	3.5	36
8	Down syndrome-like acute megakaryoblastic leukemia in a patient with Cornelia de Lange syndrome. <i>Haematologica</i> , 2018, 103, e274-e276.	3.5	9
9	Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group. <i>HemaSphere</i> , 2018, 2, e31.	2.7	40
10	Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. <i>Blood</i> , 2018, 132, 187-196.	1.4	54
11	Detection of a new heterozygous germline <i>ETV6</i> mutation in a case with hyperdiploid acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2018, 100, 104-107.	2.2	18
12	Posttransplantation relapse of pediatric chronic myelomonocytic leukemia cured using donor lymphocyte infusion. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26808.	1.5	1
13	Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 1878-1882.	7.2	8
14	Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A. <i>Leukemia Research</i> , 2018, 71, 67-74.	0.8	4
15	Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies. <i>British Journal of Haematology</i> , 2018, 182, 843-850.	2.5	18
16	Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia. <i>Leukemia</i> , 2018, 32, 2066-2069.	7.2	4
17	Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. <i>Bone Marrow Transplantation</i> , 2017, 52, 539-543.	2.4	30
18	Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With <i>NPM1</i> Mutation: A Study by the Acute Leukemia French Association Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 185-193.	1.6	227

#	ARTICLE	IF	CITATIONS
19	Comprehensive mutational profiling of core binding factor acute myeloid leukemia. <i>Blood</i> , 2016, 127, 2451-2459.	1.4	198
20	Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine. <i>Leukemia</i> , 2016, 30, 1416-1418.	7.2	16
21	Genomic Landscape and Prognosis in Pediatric Acute Myeloid Leukemia: A Study on the French ELAM02 Trial. <i>Blood</i> , 2016, 128, 1676-1676.	1.4	0
22	Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations. <i>American Journal of Hematology</i> , 2015, 90, E93-4.	4.1	12
23	Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. <i>Expert Review of Hematology</i> , 2015, 8, 43-56.	2.2	28
24	Restoration of hematopoiesis in a case of myelodysplastic syndrome associated with systemic lupus erythematosus treated with rituximab. <i>Annals of Hematology</i> , 2015, 94, 1247-1249.	1.8	9
25	Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group. <i>Leukemia Research</i> , 2015, 39, 1443-1447.	0.8	9
26	IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. <i>Oncotarget</i> , 2015, 6, 42345-42353.	1.8	92
27	Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA. <i>American Journal of Hematology</i> , 2014, 89, 610-615.	4.1	21
28	Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group. <i>Blood</i> , 2014, 124, 2327-2327.	1.4	1
29	Absolute Quantification of EVI1 Overexpression in Acute Myeloid Leukemia By RQ-PCR Analysis : A Study of the ALFA Group. <i>Blood</i> , 2014, 124, 1062-1062.	1.4	12
30	Prognostic Analysis of GATA2 Mutations in CEBPA-Mutated Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 2360-2360.	1.4	0
31	Genomic Landscape of Pediatric CBF-AML By SNP-Array Karyotyping and Extensive Mutational Analysis. <i>Blood</i> , 2014, 124, 1007-1007.	1.4	0
32	Minimal Residual Disease Monitoring In t(8;21) Acute Myeloid Leukemia Based On RUNX1-RUNX1T1 Fusion Quantification On Genomic DNA. <i>Blood</i> , 2013, 122, 1353-1353.	1.4	0
33	Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia. <i>Leukemia</i> , 2011, 25, 1661-1664.	7.2	39